Investigational therapy demonstrating 14.2-month median PFS in a phase 1 study of stage IV pancreatic ductal adenocarcinoma
GO-4305C is a multi-modal investigational therapy designed to attack cancer cells through synergistic drug interactions that produce multiple independent mechanisms of action.
The phase 1 SHARON trial in stage IV BRCA-associated pancreatic cancer demonstrated a median progression-free survival of 14.2 months (N=12). Two patients remain disease-free at 54 and 32 months. No chronic toxicities have been observed to date in the study.
Data from the SHARON trial were presented at the ESMO 2025 Congress. View our ESMO 2025 poster.
General Oncology develops drug candidates designed to overcome tumor drug resistance while minimizing chronic toxicity.
Our programs focus on metastatic cancers and other proliferative diseases where current therapies provide limited durable benefit.
GO-4305C — Clinical Stage
GO-4305C is designed to treat metastatic cancers, including pancreatic cancer.
GO-2301 — Preclinical
GO-2301 is a novel drug candidate being developed for proliferative diseases including wet age-related macular degeneration (AMD) and diabetic retinopathy, with potential future oncology applications.
